A nationwide U.S. study published in JAMA, analyzing data from 2.15 million women with breast cancer, found that choosing complementary and alternative medicine (CAM) instead of evidence-based therapy ...

I am a software developer and a 4th-year Computer Engineering student at the Turkish-German University. I have worked on numerous software projects, especially those related to healthcare. My primary ...

Healthcare is entering a new digital era. Yet existing systems still rely on fragmented data and outdated software that struggle to support truly patient-centered care. Real progress now depends on ...

BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...

A new study published in Science Advances reveals a groundbreaking approach that makes cancer cells turn against themselves by reprogramming how they die. Scientists at the Institut Pasteur and Inserm ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

Presented at the 2025 SABCS annual meeting, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease recurrence or death by 30% in early-stage ER-positive ...

Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. They not only infect and kill cancer cells, but also modulate the tumor micro-environment to enhance ...

The third-generation tyrosine kinase inhibitor olverembatinib may represent a major advance for patients with chronic myeloid leukemia and Philadelphia chromosome (Ph+) positive acute lymphoblastic ...